Why the study?
Given the high global burden and mortality of cardiac problems, this review aimed to explore the cardioprotective drug dexrazoxane.
Does dexrazoxane prevent cardiotoxicity in patients receiving anthracycline-based chemotherapy?
Does dexrazoxane prevent cardiotoxicity in patients receiving anthracycline-based chemotherapy?
Dexrazoxane is an effective cardioprotective agent for preventing anthracycline-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May support dexrazoxane regardless of baseline cardiac risk; leaves open need for confirmatory RCTs.
Heart plays a vital role in the human life survival. Now a days the global burden of heart problems is very high. There is very high mortality rate. So in this review we aimed to explore the cardioprotective drug dexrazoxane. Now, dexrazoxane has received approval for two different uses: avoiding tissue damage after anthracycline extravasation and preventing cardiotoxicity during anthracycline-based chemotherapy. Regardless of existing cardiac risk factors, the medication seems to provide cardiac protection. Dexrazoxane is a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic properties, according to the prior study. So this study suggests that the dexrazoxane will play very important role in the treatment of cardiac problems.
No takes yet. Share an insight, caveat, or question.
Rathi et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: